Humberto Antunes: Galderma
Rosalind Hill talks to Galderma’s worldwide CEO, Humberto Antunes, about company and market developments in a fast-growing industry
Read MoreRosalind Hill talks to Galderma’s worldwide CEO, Humberto Antunes, about company and market developments in a fast-growing industry
Read MoreGalderma has announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso is an alpha-2 adrenergic receptor agonist that acts rapidly and can...
Read MoreGalderma Laboratories, LP, has announced the publication of the long-term efficacy and safety results of a 1-year, open-label, non-comparative study of Mirvaso® (brimonidine) Topical Gel, 0.33% in patients with moderate...
Read MoreGalderma Laboratories, L.P. has announced that the US Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of...
Read More